Adjuvant or rescue disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 overexpression: A phase II multi-center study
机构：[1]West China Hospital of Sichuan Univertity, Chendu, China[2] West China Hospital, Sichuan University, Chengdu, Sichuan, China[3] Department of Urology, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[4] West China Hospital, Sichuan University, Chengdu, China[5] Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[6] Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[7] Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[8] Department of Radiology, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[9] Department of Pathology, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[10] Department of Urology, The First Affiliated Hospital of Xi’an Jiaotong University, Xian, China[11] The First Affiliated Hospital of Kunming Medical University, Kunming, China昆明医科大学附属第一医院
第一作者机构：[1]West China Hospital of Sichuan Univertity, Chendu, China
推荐引用方式(GB/T 7714)：
Chen Junru,Liu Haoyang,Zhu Qiyu,et al.Adjuvant or rescue disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 overexpression: A phase II multi-center study[J].JOURNAL OF CLINICAL ONCOLOGY.2024,42(16):
APA：
Chen, Junru,Liu, Haoyang,Zhu, Qiyu,Xu, Chenhao,Wei, Qiang...&Zeng, Hao.(2024).Adjuvant or rescue disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 overexpression: A phase II multi-center study.JOURNAL OF CLINICAL ONCOLOGY,42,(16)
MLA：
Chen, Junru,et al."Adjuvant or rescue disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 overexpression: A phase II multi-center study".JOURNAL OF CLINICAL ONCOLOGY 42..16(2024)
医学